Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 5, 2010, Pages 499-510

  Azevedo, L F ^a   Magro, F ^b,c   Portela, F ^c   Lago, P ^c   Deus, J ^c   Cotter, J ^c   Cremers, I ^c   Vieira, A ^c   Peixe, P ^c   Caldeira, P ^c   Lopes, H ^c   Goncalves R ^c   Reis, J ^c   Cravo, M ^c   Barros, L ^c   Ministro, P ^c   Lurdes, M ^c   Duarte, A ^c   Campos, M ^c   Carvalho, L ^c   Costa Pereira, A ^a   more..

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c IBD Portuguese Study Group (GEDII)   (Portugal)

Author keywords

Drug consumption data; Epidemiologic methods; Inflammatory bowel disease; Intestinal anti inflammatory drugs; Pharmacoepidemiology; Prevalence

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CROHN DISEASE; CROSS-SECTIONAL STUDY; ENTERITIS; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PORTUGAL; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PORTUGAL; PREVALENCE; SEX FACTORS; SULFASALAZINE;

EID: 77952782323     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1930     Document Type: Article

References (45)

1. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol 2004; 18: 463-479. (Pubitemid 38667460)
2. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517.
3. Loftus EV, Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1-20.
4. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377. (Pubitemid 351320845)
5. Tebano MT, Traversa G, Da Cas R, Loizzo A. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. Aliment Pharmacol Ther 1996; 10: 659-663. (Pubitemid 26254812)
6. Walckiers D, Sartor F. Results of an epidemiological study on drug-treated intraocular hypertension in Belgium. J Clin Epidemiol 1996; 49: 489-493. (Pubitemid 26149676)
7. Sartor F, Walckiers D. Estimate of disease prevalence using drug consumption data. Am J Epidemiol 1995; 141: 782-787.
8. Duarte-Ramos F, Cabrita J. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal. Pharmacoepidemiol Drug Saf 2006; 15: 269-274.
9. Magro F, Portela F, Lago P, et al. Inflammatory bowel disease: a patient's and caregiver's perspective. Dig Dis Sci 2009; 54: 2671-2679.
10. Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15: 176-181.
11. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol 1992; 43: 215-218.
12. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539.
13. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews 2005. Available at: http://mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD003715/frame.html [accessed on March 2008].
14. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 841-855.
15. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006. Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD000544/frame.html [Accessed March 2008].
16. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research (4th edn). Blackwell Science: Oxford, Malden, MA, 2002.
17. Casella GC, Berger RL. Statistical Inference (2nd edn). Duxbury: California, USA, 2001.
18. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Van Nostrand Reinhold Company: New York, 1982.
19. Magro F, Portela F, Lago P, et al. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm Bowel Dis 2009; 15: 1343-1350.
20. Portela F, Magro F, Lago P, et al. Ulcerative colitis in a southern European country: a national perspective. Inflamm Bowel Dis 2009. Available at: http://www3.interscience.wiley.com/journal/122648656/abstract [Accessed on October 2009].
21. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
22. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44: 287-302.
23. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753. (Pubitemid 43764536)
24. INE. Instituto Nacional de Estatística-Statistics Portugal: Dados Estatísticos-Estatísticas Territoriais. Instituto Nacional de Estatística, Lisboa, Portugal. 2008. Available at: http://www.ine.pt/ [Accessed on 15 March 2008].
25. Montgomery SM, Morris DL, Thompson NP, Subhani J, Pounder RE, Wakefield AJ. Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort. Br Med J 1998; 316: 1058-1059. (Pubitemid 28143104)
26. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14: 1553-1559. (Pubitemid 32011728)
27. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-1256.
28. Trallori G, Palli D, Saieva C, et al. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-1992). Scand J Gastroenterol 1996; 31: 892-899.
29. Daiss W, Scheurlen M, Malchow H. Epidemiology of inflammatory bowel disease in the county of Tubingen (west Germany). Scand J Gastroenterol Suppl 1989; 170: 39-43 discussion 50-55
30. Mate-Jimenez J, Munoz S, Vicent D, Pajares JM. Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. J Clin Gastroenterol 1994; 18: 27-31.
31. Vucelic B, Korac B, Sentic M, et al. Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. Int J Epidemiol 1991; 20: 216-220.
32. Vucelic B, Korac B, Sentic M, et al. Ulcerative colitis in Zagreb, Yugoslavia: incidence and prevalence 1980-1989. Int J Epidemiol 1991; 20: 1043-1047.
33. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006; 82: 332-337.
34. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-6108.
35. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-697.
36. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991; 100: 143-149.
37. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-amino-salicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8: 35-43.
38. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993; 104: 435-439.
39. Prantera C, Pallone F, Brunetti G, Cottone M. MiglioliM. Oral 5-amino-salicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992; 103: 363-368.
40. Ades AE, Sutton AJ. Multiparameter evidence synthesis in epidemiology and medical decision-making: current approaches. J R Stat Soc Ser A 2006; 169: 5-35.
41. Goubar A, Ades AE, De Angelis D, et al. Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data. J R Stat Soc Ser A 2008; 171: 541-580.
42. Sweeting MJ, De Angelis D, Hickman M, Ades AE. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics 2008; 9(4): 715-734.
43. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. J R Stat Soc Ser C 2005; 54: 385-404.
44. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl 1): i16-i35.
45. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62.